RZLT · NasdaqCM
Biotechnology · United States
Snapshot 2026-09-25 · Latest financial period 2026-03-31 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Company websiteQ4 FY2026
Published 2026-09-25
Q4 FY2026 REPORT HIGHLIGHTS
Rezolute reports seven early tumor-trial responders while the failed congenital study remains under FDA review. We examine the cash runway, economic share count and success burden in the price.
A seventh of the initial eight upLIFT participants met the response threshold; enrollment and final analysis remain unfinished.
sunRIZE failed its primary and key secondary endpoints, and FDA review has no stated completion date.
Lower R&D was offset by higher administration and stock compensation; better loss EPS reflects a larger share denominator.
June liquidity was $107.801M against $64.635M of annual operating cash use; approval and additional trials can require more capital.
Our $2.50 conditional base is below the $3.94 close, with a wide $0.25–$7.00 scenario range.
Comparable businesses
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.
| Metric | RZLTRezolute, Inc.Snapshot 2026-09-25Financial period: 2026-03-31 |
|---|---|
| Market capMarket value, converted to USD | US$379.39M |
| Forward P/EProvider forward earnings estimate | — |
| EV / EBITDAEnterprise value / trailing EBITDA | — |
| Revenue growthLatest quarter vs prior-year quarter | — |
| Operating marginLatest reported quarter | 0.0% |
| Free cash flow yieldTrailing cash flow / market cap | -11.5% |
| Net debt / EBITDANet debt / trailing EBITDA | — |
| Debt / equityTotal debt / positive book equity | 0.01x |
| Trailing P/ETrailing twelve-month earnings | — |
| Price / bookPrice / positive book equity per share | 3.52x |
| EV / salesEnterprise value / trailing revenue | — |
| Earnings growthLatest quarter vs prior-year quarter | — |
| Gross marginTrailing twelve months | 0.0% |
| Net marginTrailing twelve months | 0.0% |
| Return on equityProvider trailing return; positive equity only | -81.7% |
| Free cash flow marginTrailing free cash flow / revenue | — |
| Dividend yieldIndicated annual dividend / price | — |
| Earnings payoutProvider trailing dividend payout | 0.0% |
| Current ratioCurrent assets / current liabilities | 15.84x |
| BetaProvider historical market sensitivity | 0.61 |
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Price history loads separately.
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-25. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
FREE RESEARCH PACKET · Q4 FY2026
Rezolute reports seven early tumor-trial responders while the failed congenital study remains under FDA review. We examine the cash runway, economic share count and success burden in the price.
Research published September 24, 2026 · Download original report
Read Research PacketPresentation · 2026-09-25 · YouTube
Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.
